Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 26.53
-0.40 (-1.49%)
Feb 13, 2026, 3:00 PM CST
Aurisco Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,621 | 1,472 | 1,254 | 1,001 | 800.46 | 717.74 |
Other Revenue | 3.67 | 3.67 | 8.59 | 7.23 | 2.9 | 3.7 |
| 1,624 | 1,476 | 1,263 | 1,008 | 803.36 | 721.44 | |
Revenue Growth (YoY) | 13.73% | 16.89% | 25.24% | 25.48% | 11.36% | 24.04% |
Cost of Revenue | 660.12 | 631.38 | 564.22 | 495.51 | 408.64 | 381.12 |
Gross Profit | 964.36 | 844.36 | 698.32 | 512.57 | 394.72 | 340.32 |
Selling, General & Admin | 314.66 | 300.7 | 270.49 | 175.27 | 136 | 94.28 |
Research & Development | 154.41 | 146.34 | 136.89 | 117.26 | 69.35 | 47.35 |
Other Operating Expenses | 5.56 | 7.38 | 7.93 | 7.63 | 6.7 | 6.07 |
Operating Expenses | 476.94 | 457.96 | 419.48 | 304.36 | 211.96 | 148.44 |
Operating Income | 487.42 | 386.4 | 278.83 | 208.21 | 182.76 | 191.88 |
Interest Expense | -35.11 | -15.78 | -2.74 | -1.01 | -0.64 | - |
Interest & Investment Income | 20.35 | 18.31 | 48.25 | 4.41 | 8.94 | 7.82 |
Currency Exchange Gain (Loss) | 18.24 | 18.24 | 3.58 | 24.86 | -7.44 | -17.21 |
Other Non Operating Income (Expenses) | -8.29 | -0.89 | -1.62 | -0.63 | 0.79 | -0.53 |
EBT Excluding Unusual Items | 482.62 | 406.28 | 326.31 | 235.84 | 184.41 | 181.96 |
Gain (Loss) on Sale of Investments | 5.65 | 2.25 | - | -1.19 | - | - |
Gain (Loss) on Sale of Assets | -0.04 | -0.41 | -1.53 | -1.5 | -0.4 | -0.26 |
Asset Writedown | -0.17 | -0.17 | - | - | - | -0.05 |
Other Unusual Items | -1.65 | -1.04 | 4.3 | 7.59 | 8 | 3.46 |
Pretax Income | 486.89 | 407.39 | 329.08 | 240.75 | 192.01 | 185.74 |
Income Tax Expense | 62.35 | 52.6 | 40.01 | 32.47 | 23.73 | 28.51 |
Earnings From Continuing Operations | 424.54 | 354.79 | 289.07 | 208.28 | 168.28 | 157.23 |
Minority Interest in Earnings | - | - | 0.35 | 2.69 | 0.43 | - |
Net Income | 424.54 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 |
Net Income to Common | 424.54 | 354.79 | 289.42 | 210.96 | 168.71 | 157.23 |
Net Income Growth | 24.62% | 22.59% | 37.19% | 25.04% | 7.31% | -15.53% |
Shares Outstanding (Basic) | 399 | 399 | 408 | 406 | 402 | 374 |
Shares Outstanding (Diluted) | 399 | 399 | 408 | 406 | 402 | 374 |
Shares Change (YoY) | -3.69% | -2.21% | 0.48% | 1.00% | 7.31% | 4.58% |
EPS (Basic) | 1.06 | 0.89 | 0.71 | 0.52 | 0.42 | 0.42 |
EPS (Diluted) | 1.06 | 0.89 | 0.71 | 0.52 | 0.42 | 0.42 |
EPS Growth | 29.40% | 25.35% | 36.54% | 23.81% | - | -19.23% |
Free Cash Flow | 38.85 | -207.87 | 80.13 | -49.82 | -49.04 | 55.68 |
Free Cash Flow Per Share | 0.10 | -0.52 | 0.20 | -0.12 | -0.12 | 0.15 |
Dividend Per Share | 0.290 | 0.290 | 0.220 | 0.160 | 0.130 | 0.120 |
Dividend Growth | 31.82% | 31.82% | 37.50% | 23.08% | 8.33% | 20.00% |
Gross Margin | 59.36% | 57.22% | 55.31% | 50.85% | 49.13% | 47.17% |
Operating Margin | 30.00% | 26.18% | 22.09% | 20.65% | 22.75% | 26.60% |
Profit Margin | 26.13% | 24.04% | 22.92% | 20.93% | 21.00% | 21.79% |
Free Cash Flow Margin | 2.39% | -14.09% | 6.35% | -4.94% | -6.11% | 7.72% |
EBITDA | 574.18 | 467.76 | 352.98 | 273.15 | 234.22 | 223.9 |
EBITDA Margin | 35.35% | 31.70% | 27.96% | 27.10% | 29.15% | 31.04% |
D&A For EBITDA | 86.77 | 81.36 | 74.15 | 64.94 | 51.47 | 32.02 |
EBIT | 487.42 | 386.4 | 278.83 | 208.21 | 182.76 | 191.88 |
EBIT Margin | 30.00% | 26.18% | 22.09% | 20.65% | 22.75% | 26.60% |
Effective Tax Rate | 12.81% | 12.91% | 12.16% | 13.49% | 12.36% | 15.35% |
Revenue as Reported | 1,624 | 1,476 | 1,263 | 1,008 | 803.36 | 721.44 |
Advertising Expenses | - | 56.72 | 33.73 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.